1-20 of 118 results for subject:Screening
Librarians' tools
- Search time
- 0.234 seconds
- Solr query time
- 0.008 seconds
- Search query
- subject:Screening
- We searched for
- subject_t:Screening OR subject_ses:92923
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
My Lords, I congratulate the noble Baroness, Lady Ramsey, on her excellent initial contribution to our debates. Unlike the noble Lord, Lord Patel, my experience is that too many interests are still worshipping at a 75 year-old NHS shrine that only 25% of the population is satisfied with. The NHS...
My Lords, I congratulate the noble Baroness, Lady Ramsey, on her excellent initial contribution to our debates. Unlike the noble Lord, Lord Patel, my experience is that too many interests are still worshipping at a 75 year-old NHS shrine that only 25% of the population is satisfied with. The NHS...
To ask Her Majesty's Government what assesment has been made of funding and creating extra capacity in (1) NHS, (2) private, and (3) other laboratories, before 31 March 2021.
To ask Her Majesty's Government what assesment has been made of funding and creating extra capacity in (1) NHS, (2) private, and (3) other laboratories, before 31 March 2021.
HM Treasury approved £22 billion of spending this year for the NHS Test and Trace programme. This covers testing to meet demand over the winter. We are providing an additional £7 billion for NHS Test and Trace to support increased testing, including community testing and ongoing improvements to contact tracing. Eighty per cent of this will be directly spent on laboratories, tests and testing kits.
To ask Her Majesty's Government what is the laboratory capacity for COVID-19 tests per week available in England (1) within the NHS, and (2) in private and other laboratories; and what is the utilisation rate of that weekly capacity in each group at the latest date for which information is...
To ask Her Majesty's Government what is the laboratory capacity for COVID-19 tests per week available in England (1) within the NHS, and (2) in private and other laboratories; and what is the utilisation rate of that weekly capacity in each group at the latest date for which information is...
For the week commencing 18 January 2021 the number of tests conducted in pillar 1 was 592,698 against a capacity of 1,352,685, which is a utilisation rate of 43.82%. In pillar 2, the number of tests conducted was 3,233,418 against a capacity of 4,321,944, which is a utilisation rate of 74.81%.
To ask Her Majesty's Government whether all the laboratories available for COVID-19 tests are (1) currently, or (2) planning to be, working seven days a week and in shifts covering most of each day.
To ask Her Majesty's Government whether all the laboratories available for COVID-19 tests are (1) currently, or (2) planning to be, working seven days a week and in shifts covering most of each day.
Since the start of the pandemic, we increased the capacity of National Health Service and Public Health England laboratories, as well as setting up an entirely new nationwide network of new Lighthouse laboratories and partner laboratories to process samples. Lighthouse laboratories and partner laboratories have continued to maximise capacity. This includes recruiting staff, mobilising additional equipment and optimising workflows. All Lighthouse laboratories are now working on a 24 hours a day, seven days a week basis.
To ask Her Majesty's Government, in calculating the COVID-19 related laboratory capacity required for NHS and public health purposes in England for the period to 31 March 2021, what are their estimates of the number of tests required per week for (1) NHS staff and patients, (2) adult social care...
To ask Her Majesty's Government, in calculating the COVID-19 related laboratory capacity required for NHS and public health purposes in England for the period to 31 March 2021, what are their estimates of the number of tests required per week for (1) NHS staff and patients, (2) adult social care...
We do not publish data in the format requested.
To ask Her Majesty's Government what percentage of pathology laboratory testing capacity was available to the NHS in England for COVID-19 tests at the end of March 2020; and what is the current available capacity.
To ask Her Majesty's Government what percentage of pathology laboratory testing capacity was available to the NHS in England for COVID-19 tests at the end of March 2020; and what is the current available capacity.
Pillar 2 uses Lighthouse laboratories and has partnership arrangements with public, private and academic sector laboratories. The United Kingdom’s daily COVID-19 testing capacity passed the 500,000 on 31 October. Testing capacity in the UK across all pillars between 29 October and 4 November was at 4,367,049 tests, an increase of 21% compared to the previous week.
Her Majesty's Government whether NHS patients will be able to obtain through their GPs a test to establish if they have COVID-19 as part of their NHS primary care services; and if so, when.
Her Majesty's Government whether NHS patients will be able to obtain through their GPs a test to establish if they have COVID-19 as part of their NHS primary care services; and if so, when.
With the support of NHS England, we have been piloting COVID-19 swab testing in a small number of general practices around the United Kingdom. The aim was to improve access to testing by enabling general practitioners to test symptomatic patients who present to general practice settings, when deemed it clinically appropriate, for example for some patients who are vulnerable and may otherwise struggle to access a test through the main testing routes.
To ask Her Majesty's Government how many COVID-19 laboratory tests, excluding antibody tests, in England were completed in each calendar month of 2020, up to and including August.
To ask Her Majesty's Government how many COVID-19 laboratory tests, excluding antibody tests, in England were completed in each calendar month of 2020, up to and including August.
The Government does not publish data in the format requested. The Government publishes information, from 20 March onwards, on daily tests processed and daily testing capacity at GOV.UK. We provide data on daily testing capacity by swab tests, using polymerase chain reaction assay, within pillars 1, 2, and 4 to show if someone has COVID-19; and antibody testing of a blood sample within pillar 3 and pillar 4 to show if people have antibodies from having had COVID-19.
Her Majesty's Government how many COVID-19 tests are currently being completed each week in (1) NHS and other public sector, and (2) private, laboratories.
Her Majesty's Government how many COVID-19 tests are currently being completed each week in (1) NHS and other public sector, and (2) private, laboratories.
To provide a more comprehensive response to a number of outstanding Written Questions, this has been answered by an information factsheet Testing – note for House of Lords which is attached, due to the size of the data. A copy has also been placed in the Library
Her Majesty's Government whether there is an NHS tariff price for COVID-19 pathology tests; if so, what is their price; and if not, how are these tests priced.
Her Majesty's Government whether there is an NHS tariff price for COVID-19 pathology tests; if so, what is their price; and if not, how are these tests priced.
To provide a more comprehensive response to a number of outstanding Written Questions, this has been answered by an information factsheet Testing – note for House of Lords which is attached, due to the size of the data. A copy has also been placed in the Library
To ask Her Majesty's Government (1) what instructions were given to NHS acute hospital trusts on, or around, 15 March about discharging patients to make beds available for COVID-19 patients; (2) how many beds in total the NHS in England was trying to make available; (3) which organisation issued the...
To ask Her Majesty's Government (1) what instructions were given to NHS acute hospital trusts on, or around, 15 March about discharging patients to make beds available for COVID-19 patients; (2) how many beds in total the NHS in England was trying to make available; (3) which organisation issued the...
On 19 March 2020, the Department and the National Health Service co-published COVID-19 Hospital Discharge Service Requirements, setting out guidance on supporting the safe discharge of patients who no longer need acute care. A copy of this guidance is attached.
The guidance also sets out the steps that care providers should be taking and we provided £1.3 billion to support the process. We have provided advice to care homes throughout the pandemic in response to the latest conditions and emerging evidence.
The COVID-19 hospital discharge service requirements were expected to help free up 15,000 hospital beds across England.
On 2 June, NHS England published an analysis on discharges to care homes. This data was not previously available. The data showed that the proportion of people discharged to care homes, nursing homes and hospices between 15 March and 16 April was 2.8%.
A small number of people who have tested positive for COVID-19 may be discharged from the NHS within the 14-day period from the onset of COVID-19 symptoms and also require ongoing social care. If a care home provider does not feel they can provide the appropriate care for these individuals, the individual’s local authority should secure alternative appropriate accommodation and care for the remainder of the required isolation period.
To ask Her Majesty's Government what assessment they have made of the implications for patient access to treatment for those continuing to rely on the National Tariff Payment System to fund cancer genomic tests under the Genomic Medicine Service in England.
To ask Her Majesty's Government what assessment they have made of the implications for patient access to treatment for those continuing to rely on the National Tariff Payment System to fund cancer genomic tests under the Genomic Medicine Service in England.
Funding for cancer genomic testing is included under the National Tariff Payment System, excluding whole genome sequencing which NHS England is funding nationally, and is included within the healthcare resource group tariff payment for an individual patient. For example, epidermal growth factor receptor (EGFR) testing for lung cancer, along with oestrogen (positive/negative progesterone) receptor status and human epidermal growth factor receptor 2 (HER2) testing for breast cancer have been established tests within the National Health Service for a number of years.
Cancer genomic testing will continue to be funded by the National Tariff Payment System and the National Genomic Test Directory outlines the cancer genomic tests which will be delivered by the NHS in England.
To ask Her Majesty's Government whether they intend to introduce national funding for cancer genomic testing in England; and if so, when.
To ask Her Majesty's Government whether they intend to introduce national funding for cancer genomic testing in England; and if so, when.
Building on the 100,000 Genomes Project and existing genetic services, NHS England announced in October 2018 that over the next 18 months work to mobilise the NHS Genomic Medicine Service (GMS) would get underway. The aims of the GMS are to:
- Provide consistent and equitable care for the country’s 55 million population;
- Operate to common national standards, specifications and protocols;
- Deliver to a single national genomic testing directory – covering use of all technologies from single gene to whole genome sequencing initially for rare disease and cancer;
- Give all patients the opportunity to participate in research, for individual benefit and to inform future care; and
- Build a national genomic knowledge base to provide real world data to inform.
Through the GMS, NHS England will be exploring how to ensure that the funding flows for cancer support equity of access to testing across the country.
To ask Her Majesty's Government what steps they are taking, or plan to take, to mitigate the possibility of variation in patient access to cancer genomic testing in England resulting from Clinical Commissioning Group decision-making.
To ask Her Majesty's Government what steps they are taking, or plan to take, to mitigate the possibility of variation in patient access to cancer genomic testing in England resulting from Clinical Commissioning Group decision-making.
The Annual Report of the Chief Medical Officer 2016: Generation Genome, made clear that in order to achieve equitable access to genomic testing the National Health Service will need to implement a first-class genomic medicine service that is scalable, future proof and delivers value for money. The report also noted the work undertaken as part of the 100,000 Genomes Project. A copy of the report is attached.
Therefore, NHS England announced in October 2018 that over the next 18 months work to mobilise the NHS Genomic Medicine Service (GMS) would get underway. The aims of the GMS are to:
- Provide consistent and equitable care for the country’s 55 million population;
- Operate to common national standards, specifications and protocols;
- Deliver to a single national genomic testing directory – covering use of all technologies from single gene to whole genome sequencing initially for rare disease and cancer;
- Give all patients the opportunity to participate in research (for individual benefit and to inform future care); and
- Build a national genomic knowledge base to provide real world data to inform.
A key element of the GMS is the National Genomic Test Directory which outlines the entire repertoire of genomic tests for cancer and rare and inherited disease – from Whole Genomic Sequencing to panel tests, to tests for single genes and molecular markers – that are available as part of the NHS clinical service in England.
The NHS GMS will be supported by an informatics system, that is being developed in partnership with Genomics England. When fully operational the National Genomics Informatics Service will enable NHS England to monitor the number of genomic tests being carried out across the country and benchmark activity.
My Lords, I begin by saying what a privilege it was to serve on this inquiry, which was so skilfully chaired by the noble Lord, Lord Patel. We owe him a great deal of gratitude for ensuring the presence of scientific stars of a positive World Cup standard, who appeared...
My Lords, I begin by saying what a privilege it was to serve on this inquiry, which was so skilfully chaired by the noble Lord, Lord Patel. We owe him a great deal of gratitude for ensuring the presence of scientific stars of a positive World Cup standard, who appeared...
Perhaps I may correct a slip of the tongue in my opening remarks. I said that I had overdosed on Amendment No. 96, but of course there is no Amendment No. 96 in this group; I meant to refer to Amendment No. 91.
Perhaps I may correct a slip of the tongue in my opening remarks. I said that I had overdosed on Amendment No. 96, but of course there is no Amendment No. 96 in this group; I meant to refer to Amendment No. 91.
I am grateful to my noble friend for at least a little more than half a loaf in this area; indeed, it would be churlish of me not to recognise that I have about two-thirds of a loaf. However—there is always a ““however””—there is a real issue about Amendment No....
I am grateful to my noble friend for at least a little more than half a loaf in this area; indeed, it would be churlish of me not to recognise that I have about two-thirds of a loaf. However—there is always a ““however””—there is a real issue about Amendment No....
I had not intended to speak on the amendment, but I am so peeved at some of the Government’s reaction on the previous amendment that I want to draw a parallel between this amendment and Amendment No. 29. I want to return to the issue of a risk-based regulatory system....
I had not intended to speak on the amendment, but I am so peeved at some of the Government’s reaction on the previous amendment that I want to draw a parallel between this amendment and Amendment No. 29. I want to return to the issue of a risk-based regulatory system....
Perhaps I may make a few remarks based on my experience before and after the 1997 election of introducing the Human Rights Bill, as it was, to incorporate the European Convention on Human Rights. At the time I was a policy adviser for the then Home Secretary. It was never...
Perhaps I may make a few remarks based on my experience before and after the 1997 election of introducing the Human Rights Bill, as it was, to incorporate the European Convention on Human Rights. At the time I was a policy adviser for the then Home Secretary. It was never...
moved Amendment No. 40: 40: Clause 13, page 6, line 4, at end insert— ““( ) on the ground of persistent failure to adequately improve services following adverse periodic or special reviews under section 42 or section 44;”” The noble Lord said: This amendment is very much linked to the...
moved Amendment No. 40: 40: Clause 13, page 6, line 4, at end insert— ““( ) on the ground of persistent failure to adequately improve services following adverse periodic or special reviews under section 42 or section 44;”” The noble Lord said: This amendment is very much linked to the...